Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV

Journal of Virological Methods

Volumn 71, Issue 2, 1998, Pages 169-176

  Medina, Daniel J ^a   Tung, Peter P ^b   Nelson, Carol J ^c   Sathya, Bhavani ^a   Casareale, Domenick ^a   Strair, Roger K ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Recombinant retroviral system; Viral RNA; Zidovudine

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ANTIVIRUS AGENT; DEXTRAN SULFATE; DIDANOSINE; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIFE CYCLE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RECOMBINANT;

EID: 0031979696     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(97)00212-7     Document Type: Article

References (24)

1. Boucher C.A.B., O'Sullivan E., Mulder J.W. et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus positive subjects. J. Infect. Dis. 165:1992;105-110.
2. Haertle T., Carrera C.J., Wasson D.B., Sower L.C., Richard D.D., Carson D.A. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J. Biol. Chem. 263:1988;5870-5875.
3. Havlir, D., Eastman, S., Richman, D.D., 1995. HIV-1 kinetics: Rates of production and clearance of viral populations in asymptomatic patients treated with nevirapine. Abstract 229. 2nd National Conference: Human Retroviruses and Related Infections.
4. Ho D.D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. New Engl. J. Med. 321:1990;1621-1625.
5. Ho D.D., Neumann A.U., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
6. Kellam P., Boucher C.A., Larder B.A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA. 89:1992;1934-1938.
7. Larder B.A., Darby G., Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 243:1989;1731-1734.
8. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
9. Loveday C., Kaye S., Tenant-Flowers M., Semple M., Ayliffe U., Weller I.D., Tedder R.S. HIV-1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet. 345:1995;820-825.
10. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 47:1986;333-348.
11. Mayers D.L., McCutchan F.E., Sanders B.E., Merritt L.I., Dilworth S., Fowler A.K., Mark C.A., Ruiz N.M., Richman D.D., Roberts C.R., Burke D.S. Characterization of HIV isolates arising after prolonged zidovudine Therapy. J. Acquired Immune Defic. Syndr. 5:1992;749-759.
12. Medina D.J., Tung P.P., Lerner-Tung M.B., Nelson C.J., Mellors J. W., Strair R.K. Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine (AZT). J. Virol. 69:1995;1606-1611.
13. Medina D.J., Tung P.P., Sathya B., Strair R.K. Use of floxuridine to modulate the antiviral activity of zidovudine. AIDS Res. Hum. Retroviruses. 12:1996;965-968.
14. Mellors J., Dutschman G., Im G., Tramontana E., Winkler S.R., Cheng Y.C. In vitro selection and molecular characterization of HIV-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:1992;446-481.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. J. Immunol. Methods. 65:1983;446-451.
16. Nagy K., Young M., Baboonian C., Merson J., Whittle P., Oroszlan S. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: Evidence for a role of protease in the early phase. J. Virol. 68:1994;757-765.
17. Otto M.J., Reid C.D., Garber S., Lam P., Scarnati H., Bacheler L.T., Rayner M.M., Winslow D.L. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. J. Virol. 37:1993;2606-2611.
18. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science. 271:1996;1582-1586.
19. Reed L.J., Muench H. A simple method for estimating fifty percent end points. Am. J. Hyg. 27:1938;493-496.
20. Richman D., Shih C.K., Lowy I., Rose J., Prodanavich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. J. Proc. Natl. Acad. Sci. USA. 88:1991;11241-11251.
21. Strair R.K., Towle M.T., Heald P.W., Smith B.R. Retroviral mediated transfer and expression of exogenous genes in primary lymphoid cells: assaying for a viral-like transactivator. Blood. 76:1990;1201-1208.
22. Strair R.K., Medina D.J., Nelson C.J., Graubert T., Mellors J.W. Recombinant retroviral systems for the analysis of drug-resistant HIV. Nucleic Acids Res. 21:1993;4836-4842.
23. Wei X., Ghosh S.K., Taylor M.E. et al. Viral dynamics in HIV-1 infection. Nature. 373:1995;117-122.
24. Willey R.L., Smith D.H., Lasky L.A., Theodore T.S., Earl P.L., Moss B., Caponi D.J., Martin M.A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62:1988;139-147.